Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verrica Pharmaceuticals (VRCA)
NASDAQ:VRCA
RESEARCH TOOLSreports
Holding VRCA?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.25Last Year’s EPS
-0.53Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2019
|% Change Since: -52.45%
|Next Earnings Date:Mar 07, 2019
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in YCANTH's revenue and insurance coverage, a positive settlement reducing competition from compounded products, and promising clinical data for VP-315. However, financial losses increased, and there are operational challenges in market adoption and inventory normalization.Company Guidance
During the second quarter of 2024, Verrica Pharmaceuticals demonstrated significant progress, reporting $5.2 million in total revenues, including $4.9 million from YCANTH, their product for treating molluscum contagiosum. The company recorded a gross product margin of 93%, benefiting from previous R&D expenses. Verrica expanded its distribution network by partnering with Cencora and added Vizient as a GPO, aiming to boost demand and market share. The settlement with Dormer Laboratories marked a significant step in reducing non-FDA-approved cantharidin products in the U.S., a move expected to benefit YCANTH's demand. The company also highlighted positive Phase II results for VP-315, a potential treatment for basal cell carcinoma, with a 51% complete histologic clearance rate. Verrica's strategic focus includes capturing market share, enhancing buy-and-bill accounts, and driving adoption, aiming to address operational hurdles and capitalize on the high unmet needs in dermatology.YCANTH Revenue Growth
YCANTH recorded product revenue net of $4.9 million, reflecting growth in demand and distribution expansion.
Positive Settlement with Dormer Laboratories
Settlement with Dormer Laboratories to discontinue the sale of compounded cantharidin products in the U.S., marking a major win for YCANTH.
Advancement in Common Warts Program
Amended licensing agreement with Torii Pharmaceutical to conduct and split the cost of a global Phase III trial for YCANTH in common warts.
Successful VP-315 Phase II Study
VP-315 achieved a 51% complete histologic clearance rate in basal cell carcinoma, with an 86% overall reduction in tumor size across lesions treated.
Insurance Coverage for YCANTH
Approximately 98% of commercial lives have YCANTH coverage, with allowables visible to physicians at diagnosis.
---
VRCA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VRCA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $1.43 | $0.80 | -44.06% |
| Aug 14, 2024 | $5.27 | $3.12 | -40.80% |
| May 13, 2024 | $8.00 | $9.56 | +19.50% |
| Feb 29, 2024 | $5.72 | $5.27 | -7.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Verrica Pharmaceuticals (VRCA) report earnings?
Verrica Pharmaceuticals (VRCA) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Verrica Pharmaceuticals (VRCA) earnings time?
Verrica Pharmaceuticals (VRCA) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VRCA EPS forecast?
VRCA EPS forecast for the fiscal quarter 2024 (Q4) is -0.25.
---